ES2525497T3 - Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico - Google Patents

Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico Download PDF

Info

Publication number
ES2525497T3
ES2525497T3 ES14172398.1T ES14172398T ES2525497T3 ES 2525497 T3 ES2525497 T3 ES 2525497T3 ES 14172398 T ES14172398 T ES 14172398T ES 2525497 T3 ES2525497 T3 ES 2525497T3
Authority
ES
Spain
Prior art keywords
acid ester
controlled release
fumaric acid
release compositions
pharmaceutical controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14172398.1T
Other languages
English (en)
Other versions
ES2525497T1 (es
Inventor
Henrik Nilsson
Florian SCHÖNHARTING
Bernd W. Müller
Joseph R. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forward Pharma AS
Original Assignee
Forward Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50726313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2525497(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forward Pharma AS filed Critical Forward Pharma AS
Publication of ES2525497T1 publication Critical patent/ES2525497T1/es
Application granted granted Critical
Publication of ES2525497T3 publication Critical patent/ES2525497T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica de liberación controlada por el Ph para uso oral que consiste en fumarato de dimetilo como principio activo, en la que la composición está dotada de un recubrimiento entérico, en la que la dosificación diaria es de desde 480 hasta 720 mg de principio activo administrado en de una a tres dosis para su uso en el tratamiento de artritis psoriásica, neurodermatitis, enfermedad inflamatoria del intestino o una enfermedad autoinmunitaria.
ES14172398.1T 2004-10-08 2005-10-07 Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico Active ES2525497T3 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
DK200401546 2004-10-08
DKPA200401546 2004-10-08
DKPA200401736 2004-11-10
DK200401736 2004-11-10
DK200500211 2005-02-11
DKPA200500211 2005-02-11
DK200500419 2005-03-23
DKPA200500419 2005-03-23
US69151305P 2005-06-16 2005-06-16
US691513P 2005-06-16

Publications (2)

Publication Number Publication Date
ES2525497T1 ES2525497T1 (es) 2014-12-23
ES2525497T3 true ES2525497T3 (es) 2015-10-09

Family

ID=50726313

Family Applications (5)

Application Number Title Priority Date Filing Date
ES14172390.8T Active ES2525495T3 (es) 2004-10-08 2005-10-07 Composiciones farmacéuticas de liberación controlada que comprenden un éster del ácido fumárico
ES14172398.1T Active ES2525497T3 (es) 2004-10-08 2005-10-07 Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
ES10182198T Active ES2387192T3 (es) 2004-10-08 2005-10-07 Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
ES05789026.1T Active ES2582942T3 (es) 2004-10-08 2005-10-07 Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
ES14172396.5T Pending ES2523796T1 (es) 2004-10-08 2005-10-07 Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14172390.8T Active ES2525495T3 (es) 2004-10-08 2005-10-07 Composiciones farmacéuticas de liberación controlada que comprenden un éster del ácido fumárico

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES10182198T Active ES2387192T3 (es) 2004-10-08 2005-10-07 Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
ES05789026.1T Active ES2582942T3 (es) 2004-10-08 2005-10-07 Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
ES14172396.5T Pending ES2523796T1 (es) 2004-10-08 2005-10-07 Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico

Country Status (19)

Country Link
US (29) US20140099364A2 (es)
EP (9) EP2965751A1 (es)
JP (5) JP2008515822A (es)
CY (5) CY1113792T1 (es)
DE (4) DE14172396T1 (es)
DK (4) DK1799196T3 (es)
ES (5) ES2525495T3 (es)
FR (1) FR15C0074I2 (es)
HK (1) HK1108836A1 (es)
HR (1) HRP20170677T1 (es)
HU (3) HUE028342T2 (es)
LT (2) LT2801354T (es)
LU (1) LU92871I2 (es)
ME (2) ME02253B (es)
PL (4) PL2316430T3 (es)
PT (4) PT2316430E (es)
RS (2) RS55936B1 (es)
SI (4) SI2316430T1 (es)
WO (1) WO2006037342A2 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
WO2012136761A1 (en) * 2011-04-08 2012-10-11 Bracco Imaging Spa Process for the preparation of a sulfated derivative of 3,5-diiodo-o-[3-iodophenyl]-l-tyrosine
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
MXPA06002657A (es) 2003-09-09 2006-06-05 Fumapharm Ag Uso de derivados de acido fumarico para el tratamiento de insuficiencia cardiaca y asma.
WO2006037342A2 (en) 2004-10-08 2006-04-13 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
JP5165582B2 (ja) * 2005-12-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルペプチダーゼ−４インヒビターとメトホルミンとを組み合わせた医薬組成物
CA2658804A1 (en) 2006-07-25 2008-01-31 Vecta Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi
PT2139467T (pt) 2007-02-08 2016-12-16 Biogen Ma Inc Neuroproteção em doenças desmielinizantes
PL2137537T3 (pl) 2007-02-08 2013-10-31 Biogen Ma Inc Kompozycje i zastosowania do leczenia stwardnienia rozsianego
CA2806444C (en) 2008-08-19 2016-02-23 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate
WO2010079221A1 (en) * 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
HK1252751A1 (zh) * 2009-01-09 2019-05-31 Fwp Ip Aps 包含溶蝕骨架中的一種或多種富馬酸酯的藥物製劑
PL2564839T3 (pl) 2009-01-09 2016-11-30 Preparat farmaceutyczny obejmujący jeden lub więcej estrów kwasu fumarowego i matrycę erozyjną
NZ595941A (en) * 2009-04-29 2014-02-28 Biogen Idec Inc Treatment of neurodegeneration and neuroinflammation
PL2533634T3 (pl) 2010-02-12 2016-04-29 Biogen Ma Inc Neuroprotekcja w chorobach demielinizacyjnych
EA029077B1 (ru) * 2010-03-09 2018-02-28 Алкермес Фарма Айэленд Лимитед Устойчивая к спирту фармацевтическая лекарственная форма
KR20140035995A (ko) 2011-06-08 2014-03-24 바이오겐 아이덱 엠에이 인코포레이티드 고순도 및 결정질 다이메틸 푸마레이트의 제조 방법
EP2782561A1 (en) * 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
WO2013076216A1 (en) 2011-11-24 2013-05-30 Synthon Bv Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CN114146079A (zh) 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
JP5918395B2 (ja) 2012-02-07 2016-05-18 ゼノポート，インコーポレイティド モルホリノアルキルフマレート化合物、医薬組成物及び使用方法
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014100728A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium substituted fumarate derivatives
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
WO2015017762A1 (en) * 2013-08-01 2015-02-05 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
JP2016528302A (ja) * 2013-08-26 2016-09-15 フォーワード・ファルマ・アクティーゼルスカブＦｏｒｗａｒｄ Ｐｈａｒｍａ Ａ／Ｓ 低１日用量で投与するためのフマル酸ジメチルを含む医薬組成物
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
DK3079666T3 (da) * 2013-12-12 2021-03-22 Almirall Sa Farmaceutiske sammensætninger omfattende dimethylfumarat
US10172794B2 (en) 2013-12-13 2019-01-08 Biogen Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
EP3650042A1 (en) 2014-03-14 2020-05-13 Biogen MA Inc. Dimethyl fumarate and vaccination regimens
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2015161113A1 (en) * 2014-04-16 2015-10-22 Zynga Inc. Systems and methods of incentivizing game play
AU2015328676B2 (en) * 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
KR102283582B1 (ko) 2014-12-23 2021-07-30 한미약품 주식회사 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
WO2016113754A2 (en) * 2015-01-14 2016-07-21 Leiutis Pharmaceuticals Pvt, Ltd. Novel oral dosage forms of dimethyl fumarate
ES2879611T3 (es) * 2015-02-08 2021-11-22 Alkermes Pharma Ireland Ltd Composiciones de profármaco de monometilfumarato
US20180064653A1 (en) * 2015-03-17 2018-03-08 Hetero Labs Limited Pharmaceutical compositions of dimethyl fumarate
MA41785A (fr) * 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
AU2016273068A1 (en) * 2015-06-01 2017-12-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
AU2016279997B2 (en) * 2015-06-17 2021-10-21 Biogen Ma Inc. Dimethyl fumarate particles and pharmaceutical compositions thereof
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
WO2017129370A1 (en) * 2016-01-28 2017-08-03 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of a granulate comprising dimethyl fumarate
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2017139331A1 (en) * 2016-02-11 2017-08-17 Biogen Ma Inc. Pharmaceutical bead formulations comprising dimethyl fumarate
WO2018234584A1 (en) 2017-06-23 2018-12-27 Almirall, S.A. PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
TR201818293A2 (tr) * 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
RU2742745C1 (ru) * 2019-09-24 2021-02-10 Акционерное общество "Исследовательский Институт Химического Разнообразия" Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
JP2023525079A (ja) 2020-05-06 2023-06-14 アンシス・エスア フマレート関連疾患の併用療法
CA3216640A1 (en) 2021-05-28 2022-12-01 Amgen Inc. Formulations of apremilast
WO2023084320A1 (en) * 2021-11-11 2023-05-19 V-Ensure Pharma Technologies Private Limited Reconstitutable, single use antidiabetic compositions
US20240010618A1 (en) * 2021-12-23 2024-01-11 Glenmark Lofe Science Limited Process for the preparation of brivaracetam
CN116524199B (zh) * 2023-04-23 2024-03-08 江苏大学 一种基于PReNet渐进式网络的图像去雨方法及装置

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2764609A (en) * 1953-07-24 1956-09-25 Monsanto Chemicals Isomerization of dialkyl maleates to dialkyl fumarates
US3078302A (en) * 1958-09-25 1963-02-19 Monsanto Chemicals Production of dialkyl fumarates
GB1153927A (en) 1966-08-25 1969-06-04 Wilhelm Hoerrmann Medicinal Composition Suitable For Treating Diseases Of The Retina
US4952594A (en) * 1973-06-18 1990-08-28 Mercer James B Reagents and method for therapeutic treatment of multiple sclerosis
DE2530372A1 (de) 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2703964A1 (de) 1975-07-08 1978-08-03 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
US4145438A (en) * 1975-09-10 1979-03-20 Fisons Limited Method for treatment of eczema or psoriasis
DE2621214C3 (de) 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE2732131A1 (de) 1977-07-15 1979-01-25 Bayer Ag Verfahren zur herstellung von seitenstaendige hydroxylgruppen aufweisenden isocyanat-polyadditionsprodukten
DE2749188C2 (de) 1977-11-03 1981-11-12 Bayer Ag, 5090 Leverkusen Vorrichtung zum automatischen Einführen eines schnellaufenden Fadens in einen Fadenführungskanal einer Fadenbehandlungsvorrichtung
DE2840498C2 (de) 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmazeutische Zubereitungen zur Behandlung von Psoriasis
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US4693896A (en) 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
US4855305A (en) 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
DE3711155A1 (de) * 1987-04-02 1988-10-13 Bayer Ag Verfahren zur herstellung von maleinsaeuredimethylester
IL83775A (en) 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) * 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4911917A (en) * 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
US4965252A (en) 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
GB2253346A (en) 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
US5484610A (en) 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
US5246947A (en) * 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
FR2694693B1 (fr) 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
ES2149250T3 (es) * 1993-04-23 2000-11-01 Novartis Ag Dispositivo para la administracion de medicamentos con liberacion controlada.
US5434185A (en) 1993-05-17 1995-07-18 The University Of Kentucky Research Foundation Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
PL179910B1 (pl) * 1994-05-06 2000-11-30 Pfizer Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL
US5589504A (en) * 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5804203A (en) * 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
WO1996032942A1 (en) 1995-04-19 1996-10-24 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
EP1611885A1 (en) 1996-07-26 2006-01-04 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
BR9814772A (pt) 1998-01-22 2000-10-24 Asta Medica Ag Composições farmacêuticas sólidas que contêm miltefosina para administração oral no tratamento de leishmaniose
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
ATE267589T1 (de) * 1998-04-03 2004-06-15 Egalet As Zusammensetzung mit kontrollierter wirkstoff- freisetzung
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
KR100297705B1 (ko) * 1999-03-29 2001-10-29 김덕중 낮은 온저항과 높은 항복전압을 갖는 전력용 반도체소자
US6537584B1 (en) * 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
WO2001060780A1 (fr) * 2000-02-15 2001-08-23 Showa Denko K.K. Procede de production d'ester fumarique
WO2001060778A2 (en) * 2000-02-16 2001-08-23 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
IT1317042B1 (it) 2000-06-14 2003-05-26 Biosalts Srl Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono.
EP1172101A1 (en) * 2000-06-20 2002-01-16 Helsinn Healthcare S.A. The use of nimesulide for the treatment of psoriasis and psoriatic arthritis
WO2002002190A2 (en) * 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
JP2004523511A (ja) * 2001-01-12 2004-08-05 フーマファーム アーゲー フマル酸アミド類
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
AU2002325192B2 (en) 2001-07-06 2008-05-22 Veloxis Pharmaceuticals, Inc. Controlled agglomeration
NO20014746D0 (no) 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
US7206276B2 (en) * 2001-10-12 2007-04-17 Konica Corporation Objective lens, optical element, optical pick-up apparatus and optical information recording and/or reproducing apparatus equipped therewith
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2466504A1 (en) 2001-11-13 2003-05-22 Pharmacia Corporation Oral dosage form of a sulfonamide prodrug
US6613800B1 (en) * 2001-12-03 2003-09-02 Steven A. Smith Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
WO2003077897A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
DE10214031A1 (de) 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
US20030185915A1 (en) * 2002-03-28 2003-10-02 Jaime Carlo Synergetic composition for the treatment of psoriasis and other skin disorders and method therefor
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
US20030219456A1 (en) * 2002-05-21 2003-11-27 Taing Ok Method of utilization of zygosaccharomyces rouxii
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
ATE325115T1 (de) 2002-08-19 2006-06-15 Glaxo Group Ltd Pyrimidinderivate als selektive cox-2-inhibitoren
ES2553107T3 (es) 2003-03-27 2015-12-04 Santosolve As Composición anti-inflamatoria basada en compuestos de estroncio
EP2266585B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US20060216358A1 (en) 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
JP4861817B2 (ja) 2003-05-07 2012-01-25 オステオロジックス エイ／エス 軟骨および／または骨の症状の予防および／または治療のためのストロンチウムを用いる併用治療
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
PL196544B1 (pl) 2003-08-08 2008-01-31 Biovail Lab Int Srl Tabletka o zmodyfikowanym uwalnianiu
MXPA06002657A (es) * 2003-09-09 2006-06-05 Fumapharm Ag Uso de derivados de acido fumarico para el tratamiento de insuficiencia cardiaca y asma.
CA2555114C (en) 2004-03-31 2012-05-29 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
TW200603792A (en) 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
CN1245873C (zh) 2004-08-21 2006-03-22 王立峰 富马酸二甲酯微胶囊及其制备方法
WO2006037342A2 (en) 2004-10-08 2006-04-13 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
CN101056624A (zh) 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP1812374A1 (en) 2004-11-10 2007-08-01 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
DE102005022845A1 (de) * 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
US20070071819A1 (en) * 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
AU2006265113A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007006307A2 (en) 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
EP2186819A1 (en) 2005-07-07 2010-05-19 Aditech Pharma AG Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
WO2007042035A2 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007042034A1 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
KR100917657B1 (ko) * 2006-02-15 2009-09-18 주식회사 머젠스 산화환원 효소에 의해 ｎａｄ（ｐ）／ｎａｄ（ｐ）ｈ비율을 조절하는 방법
WO2007148744A1 (ja) 2006-06-21 2007-12-27 Santen Pharmaceutical Co., Ltd. フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
US20080213165A1 (en) 2006-09-01 2008-09-04 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods
PL2137537T3 (pl) * 2007-02-08 2013-10-31 Biogen Ma Inc Kompozycje i zastosowania do leczenia stwardnienia rozsianego
PT2139467T (pt) 2007-02-08 2016-12-16 Biogen Ma Inc Neuroproteção em doenças desmielinizantes
US20100052621A1 (en) 2007-04-12 2010-03-04 Mamoru Aoki Power system and set battery charging method
WO2008134013A2 (en) 2007-04-25 2008-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical excipient complex
US20080274182A1 (en) 2007-05-03 2008-11-06 Regina Helena Alida Boekema Tablet coatings made from modified carboxymethylcellulose materials
CA2690956C (en) 2007-07-01 2017-01-03 Joseph Peter Habboushe Combination tablet with chewable outer layer
KR20090028047A (ko) * 2007-09-13 2009-03-18 경북대학교 산학협력단 디메틸푸마레이트의 신규 용도
CN101318901A (zh) 2008-06-17 2008-12-10 健雄职业技术学院 一种富马酸二甲酯的合成新工艺
CA2806444C (en) * 2008-08-19 2016-02-23 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate
PL2564839T3 (pl) 2009-01-09 2016-11-30 Preparat farmaceutyczny obejmujący jeden lub więcej estrów kwasu fumarowego i matrycę erozyjną
WO2010079221A1 (en) 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
CN101475477A (zh) 2009-01-23 2009-07-08 上海化学试剂研究所 反丁烯二酸二甲酯的制备方法
US20120020954A1 (en) * 2009-03-30 2012-01-26 Anat Achiron Methods of predicting clinical course and treating multiple sclerosis
NZ595941A (en) 2009-04-29 2014-02-28 Biogen Idec Inc Treatment of neurodegeneration and neuroinflammation
CN101701943A (zh) 2009-11-05 2010-05-05 宁波中普检测技术服务有限公司 气相色谱-质谱联用测定产品中富马酸二甲酯的方法
PL2533634T3 (pl) 2010-02-12 2016-04-29 Biogen Ma Inc Neuroprotekcja w chorobach demielinizacyjnych
AU2012258558A1 (en) 2011-05-26 2013-05-02 Biogen Ma Inc. Methods of treating multiple sclerosis and preserving and/or increasing myelin content
KR20140035995A (ko) 2011-06-08 2014-03-24 바이오겐 아이덱 엠에이 인코포레이티드 고순도 및 결정질 다이메틸 푸마레이트의 제조 방법
WO2013076216A1 (en) 2011-11-24 2013-05-30 Synthon Bv Controlled release particles comprising dimethyl fumarate
CN114146079A (zh) 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
KR102092289B1 (ko) * 2013-06-03 2020-03-23 삼성전자주식회사 전자 기기 및 이의 문서 작성 방법
US10172794B2 (en) 2013-12-13 2019-01-08 Biogen Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
AU2015328676B2 (en) 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2017040272A1 (en) 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
WO2017151184A1 (en) 2016-02-29 2017-09-08 Banner Life Sciences Llc Fumarate ester dosage forms
US10523918B2 (en) 2017-03-24 2019-12-31 Samsung Electronics Co., Ltd. System and method for depth map

Also Published As

Publication number Publication date
PL2316430T3 (pl) 2012-11-30
US20180325855A1 (en) 2018-11-15
HK1108836A1 (zh) 2008-05-23
EP3470064A1 (en) 2019-04-17
CY1116599T1 (el) 2016-08-31
PT2801355E (pt) 2015-09-18
US20210220318A1 (en) 2021-07-22
DK2801355T3 (en) 2015-07-06
EP2965751A1 (en) 2016-01-13
ES2525495T1 (es) 2014-12-23
US20140037740A1 (en) 2014-02-06
US20190343787A1 (en) 2019-11-14
US20140199387A1 (en) 2014-07-17
US20140199393A1 (en) 2014-07-17
EP2792349A3 (en) 2014-12-17
HUS1500057I1 (hu) 2016-04-28
US20170014367A2 (en) 2017-01-19
LT1799196T (lt) 2016-09-12
US20140037720A1 (en) 2014-02-06
PT2316430E (pt) 2012-06-26
US20140199392A1 (en) 2014-07-17
RS54187B1 (en) 2015-12-31
US20190091191A1 (en) 2019-03-28
US20130315993A1 (en) 2013-11-28
CY1113792T1 (el) 2016-07-27
EP2316430A1 (en) 2011-05-04
US20170112793A2 (en) 2017-04-27
SI2316430T1 (sl) 2012-09-28
US20190117613A1 (en) 2019-04-25
US20140199386A1 (en) 2014-07-17
EP3093012A1 (en) 2016-11-16
HUE031950T2 (en) 2017-08-28
US20180028483A1 (en) 2018-02-01
EP2801355A1 (en) 2014-11-12
FR15C0074I1 (es) 2015-12-25
EP2801354B1 (en) 2017-02-08
US20090304790A1 (en) 2009-12-10
LT2801354T (lt) 2017-06-26
WO2006037342A2 (en) 2006-04-13
JP2008515822A (ja) 2008-05-15
LU92871I9 (es) 2019-02-27
PL2801354T3 (pl) 2017-08-31
ES2523796T1 (es) 2014-12-01
US20140099364A2 (en) 2014-04-10
JP2018087220A (ja) 2018-06-07
US20190201368A1 (en) 2019-07-04
US11229619B2 (en) 2022-01-25
FR15C0074I2 (fr) 2016-04-22
SI2801355T1 (sl) 2015-09-30
US20140199388A1 (en) 2014-07-17
US20220105064A1 (en) 2022-04-07
DE202005022112U1 (de) 2014-04-24
DK2316430T3 (da) 2012-07-23
US20180098957A1 (en) 2018-04-12
US20160136125A2 (en) 2016-05-19
CY1117937T1 (el) 2017-05-17
EP1799196B1 (en) 2016-06-22
ES2525497T1 (es) 2014-12-23
EP1799196A2 (en) 2007-06-27
US11052062B2 (en) 2021-07-06
US20150024049A1 (en) 2015-01-22
RS55936B1 (sr) 2017-09-29
PL1799196T3 (pl) 2016-12-30
US20160271093A2 (en) 2016-09-22
DE14172396T1 (de) 2015-01-08
US20130316003A1 (en) 2013-11-28
US20140199390A1 (en) 2014-07-17
DK2801354T3 (en) 2017-05-15
CY2015045I1 (el) 2016-08-31
ME02746B (me) 2018-01-20
US20140193495A1 (en) 2014-07-10
LU92871I2 (fr) 2016-01-13
US20180263947A1 (en) 2018-09-20
ME02253B (me) 2015-12-31
EP2801355B1 (en) 2015-05-20
WO2006037342A3 (en) 2006-07-20
US20170231941A1 (en) 2017-08-17
DE14172398T1 (de) 2015-01-08
US20140200272A1 (en) 2014-07-17
EP2792349A2 (en) 2014-10-22
CY2015045I2 (el) 2016-08-31
PT1799196T (pt) 2016-08-31
CY1118887T1 (el) 2018-01-10
JP6896792B2 (ja) 2021-06-30
SI1799196T1 (sl) 2016-10-28
EP3459532A1 (en) 2019-03-27
JP2013064007A (ja) 2013-04-11
ES2582942T3 (es) 2016-09-16
DE14172390T1 (de) 2014-12-31
DK1799196T3 (en) 2016-08-15
EP2316430B8 (en) 2012-07-11
ES2387192T3 (es) 2012-09-17
ES2525495T3 (es) 2017-07-26
JP2019147832A (ja) 2019-09-05
EP2801354A1 (en) 2014-11-12
HRP20170677T1 (hr) 2017-09-08
JP2015227350A (ja) 2015-12-17
SI2801354T1 (sl) 2017-07-31
US20140200273A1 (en) 2014-07-17
HUE028342T2 (en) 2016-12-28
EP2316430B1 (en) 2012-06-06
PL2801355T3 (pl) 2015-10-30
US20140205659A1 (en) 2014-07-24
US20190091192A1 (en) 2019-03-28
US20190091193A1 (en) 2019-03-28
PT2801354T (pt) 2017-06-05

Similar Documents

Publication Publication Date Title
ES2525497T3 (es) Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
RS52922B (en) PREPARATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND THEIR USES
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
JP2015038135A5 (es)
HN2008001666A (es) Derivados acidos de cicloalquilamino
AR068820A1 (es) Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica y uso
CO6220902A2 (es) Formulacion en polvo del valganciclovir
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
CO6270220A2 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamotorio no esteroide y un agente inhibidor de la xantino oxidasa utiles para el control y el tratamiento de la gota artritis gotosa y enfermedades relacionadas
GT201000064A (es) Formulaciones galénicas de alisquireno
AR072889A1 (es) Combinacion coccidicida para uso veterinario
MY150069A (en) Formulation for prolonged release of active ingredients of medicaments
PE20090316A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias
AR067465A1 (es) Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico